Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE

Abstract Introduction Although acute and preventive treatments for migraine are commonly given in combination, data on the real-world effectiveness of ubrogepant as an acute treatment when used with an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (with or without onabotulinumtoxin...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Richard B. Lipton, Janette Contreras-De Lama, Daniel Serrano, Ella Engstrom, Nicolai D. Ayasse, Weijie Poh, François Cadiou, Aubrey Manack Adams
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Adis, Springer Healthcare 2023-11-01
Serie:	Neurology and Therapy
Soggetti:	CGRP Effectiveness Migraine Real-world Satisfaction Ubrogepant
Accesso online:	https://doi.org/10.1007/s40120-023-00556-8
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!